Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBERTY: Erenumab 140 mg monthly vs placebo in treatment-resistant episodic migraine
2016-002211-18Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in migraine comparing Erenumab 140 mg monthly with Placebo monthly (2 arms). Primary endpoint: Proportion of patients with ≥50% reduction in monthly migraine days at Month 3. Started Jul 2016; status: completed.
02
Drugs
erenumab
03
Conditions
migraine
Beyond the preview
Go deeper on 2016-002211-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002211-18.